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INTRODUCTION
approaches will be to elicit sterilising cure such that cccDNA is removed with no long-term risk of 143 relapse (7). 156 clearance rate, leaving nine relevant studies. As for the meta-analysis, the majority (8/9) were in cumulative clearance of 3.5% (21). Older age was associated with clearance in two cohorts (23, 175 29) . The role of treatment in clearance is inconsistent, with NA treatment associated with clearance 176 in some cohorts (21, 25) but not in others (26).
178
HBsAg levels can be used to determine treatment response, although this has been more reliably 179 reported for PEG-IFN2α treatment than for NAs (30, 31), as it implies reduction or removal of the 180 cccDNA reservoir ( Fig 1C) . Current UK guidelines recommend quantitative HBsAg and HBeAg 181 measurement before starting treatment and at weeks 12, 24 and 48 during treatment, followed by 182 6 monthly measurement during long term therapy (32). European Association for the Study of the 183 Liver (EASL) guidelines recommend quantitative HBsAg measurement annually in treated patients 184 if HBV DNA is undetectable, as well as using HBsAg levels to inform the decision to stop treatment 185 (1). EASL guidelines also recommend HBeAg measurement as part of the initial clinical 186 assessment, and list HBeAg loss as one of the serological responses to treatment, but do not 187 specify a frequency for follow-up testing (1).
189
International targets arising from the United Nations 'sustainable development goals' have set a 190 challenge for elimination of CHB infection as a public health threat by the year 2030 (33) .
191
Recognising the multi-lateral approaches that will be required to reach this ambitious goal, we here 192 focus on two inter-related aims:
We set out to showcase how longitudinal data for individuals with CHB can be collected 194 through an unbiased electronic pipeline that collates, cleans and anonymises routinely- 
214

Description of a clinical cohort of chronic HBV infection 215
We identified 553 individuals who tested HBsAg-positive during the six-year period 2011-2016,
216
inclusive. Of these, 319 met inclusion criteria for further analysis (as shown in Table 1 ; Fig 2) .
217
Characteristics of the cohort are summarised in Table 2 HBsAg clearance occurred over a median time of 157 weeks (95% CI 90-239 weeks) ( Fig 4A) .
256
Comparing individuals on treatment (n=4) vs. off treatment (n=9) during or in the 12 months prior to treatment vs. 157 weeks in those not on treatment; Fig 4B) . 
271
We also reviewed treatment data for the 279 individuals who did not clear HBsAg, and were able 272 to retrieve data for 171 of these (61%). Among these, 131 (77%) had received treatment of some 273 type, and 40 had never been treated (23%). We were not able to determine robust time-frames for 282 283 individuals being HBeAg-positive (p=0.025). We documented HBeAg clearance in 44/81 (54%) of 288 these individuals over the observed time period (Table 3) 
292
55%) and 52 weeks (95% CI 14-133) for untreated individuals (n=19, 43%); treatment data were 293 not available for 1 individual (Fig 4E,F) . We also reviewed treatment data for those who did not 294 clear HBeAg, and were able to retrieve data for 27 of these (73%). Of these, 24 (89%) had 
309
Relationship between HBsAg and HBV DNA
310
In 11/13 HBsAg clearers, HBV DNA was below the limit of detection (<20 IU/ml) throughout; in two The NIHR HIC approach, involving the generation of standardised datasets based upon routinelywith other university-hospital partnerships, we will increase the breadth, depth, and quality of the insights into the prognostic information that can be captured from this biomarker could be relevant 391 to predicting patient outcomes and providing stratification of therapy. In this study, we did not have 392 routine access to HBsAg levels >1000 IU/ml, but as these data progressively become available, 
490
We cleaned and analysed data using R and the data. 
HBeAg categories
HBeAg persistently positive • HBeAg above the limit of detection (≥20 IU/ml) for all timepoints.
HBeAg persistently negative • HBeAg below the limit of detection (<20 IU/ml) for all timepoints.
HBeAg clearer
• HBeAg detectable at ≥ 2 independent timepoints and subsequently falls below the limit of detection for ≥ 2 consecutive timepoints • HBeAg does not rebound above the limit of detection Non HBeAg Clearer
• All individuals who are not classified as persistently HBeAg positive, negative or as an HBeAg clearer a Records with free text or uninterpretable data were removed from analysis 
Category of influence
Examples of the effect on data integrity
Patient factors
• Many individuals with CHB infection globally are not diagnosed; those with data available for clinical analysis represent a distinct minority group who have been able to access healthcare and follow-up (44). • Patients are lost to follow-up or move between regions.
• HBV diagnosis rarely occurs in acute infection, so the duration of infection prior to clearance is unknown. • HBsAg clearance is a relatively infrequent event and thus patient numbers for analysis are small. • Description of a changing cohort is challenging e.g. age changes over time, patients start and stop therapy.
Healthcare factors
• Different assays are not always requested simultaneously, thus limiting the correlation between variables (e.g. HBV DNA vs HBsAg). • Follow-up occurs over a variety of different time frames, with different intervals between follow up visits; clearance durations may therefore be over-estimated due to infrequent sampling. • Treatment can alter the dynamics of biomarkers (e.g. ALT, HBV DNA).
Laboratory factors
• Assay platforms change over time, which may alter sensitivity, specificity and limits of detection. • Quantitative assays have upper and lower limits of quantification; values outside the window of detection cannot be analysed. • False positive or false negative tests may occur.
• Certain data are not routinely generated or captured (e.g. HBV genotype).
Data factors
• Results are captured by a variety of different electronic systems (electronic patient record, electronic laboratory systems, pharmacy systems, hand-written clinical notes, dictated clinic letters). • Different healthcare professionals may not record data consistently and coding is subject to errors. • Free text entries in laboratory reporting can lead to errors or ambiguities (e.g. use of comma vs. full stop for decimal point). Certain parameters are not consistently recorded, e.g. ethnicity. • The electronic pipeline only collects certain pre-defined data (e.g. for HIV, HCV, HDV we were only able to access viral load data, not antibody tests, and therefore we do not know the denominator of total tests performed). • Treatment data may not be recorded electronically (often recorded as part of paper notes, making them more difficult to trace); start dates often not documented for patients on long-term treatment. • Poor continuity of data when patients are transferred between different healthcare providers. 
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The data warehouse receives data from operational systems within the hospital such as electronic data product are selected using the definitions in the metadata catalogue the mappings for these 599 are retrieved from the master data store and data retrieved from the integrated data store to create 600 the final data product. 
